Changes in Beneficial Ownership · 4
Rhythm Pharmaceuticals, Inc.
RYTMNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-09-14
- Issuer
- RHYTHM PHARMACEUTICALS, INC.
- Issuer CIK
- 0001649904
- Trading symbol
- RYTM
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Meeker David P
- Reporting owner CIK
- 0001385155
- Relationship
- Director · Officer
- Officer title
- President and CEO
- Address
- C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON, MA, 02116
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-14 | M · Form 4[F1] | 50,000 | A | 6.05 | 289,258[F2] | D |
| Common Stock | 2026-09-14 | S · Form 4[F1] | 6,439 | D | 101.7464[F3] | 282,819 | D |
| Common Stock | 2026-09-14 | S · Form 4[F1] | 30,746 | D | 102.347[F4] | 252,073 | D |
| Common Stock | 2026-09-14 | S · Form 4[F1] | 8,698 | D | 103.43[F5] | 243,375 | D |
| Common Stock | 2026-09-14 | S · Form 4[F1] | 1,817 | D | 104.5487[F6] | 241,558 | D |
| Common Stock | 2026-09-14 | S · Form 4[F1] | 2,300 | D | 105.19[F7] | 239,258 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy) | 6.05 | 2026-09-14 | M · Form 4 | 50,000 | D | 0 | [F8] | 2027-02-07 | Common Stock | 50,000 | 15,431 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6
- F2
- Includes 242 shares acquired under the Rhythm Pharmaceuticals, Inc. employee stock purchase plan on 2-28-2026.↩ 1
- F3
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.96 to $101.95 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
- F4
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.96 to $102.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
- F5
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.97 to $103.96 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
- F6
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.97 to $104.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
- F7
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.00 to $105.31 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
- F8
- The stock options were granted on February 8, 2017 and vested and became exercisable in three equal annual installments measured from January 6, 2017.↩ 1
Signature 1
- Signed
- /s/ Stephen Vander Stoep, attorney-in-fact for David P. Meeker
- Date
- 2026-09-14